Patient preferences for reducing toxicities of treatments for gastrointestinal stromal tumor (GIST)

201117 citationsJournal Articlegold Open Access

Authors

Brett Hauber · Novartis (United States)

Juan Marcos González · Novartis (United States)

John Coombs · Life Raft Group

L. A. Sirulnik · Tris Pharma (United States)

Palacios · Tris Pharma (United States)

Scherzer · Tris Pharma (United States)

Abstract

All toxicities included in the study are important to patients. Treating or reducing severe toxicities is much more important to patients than treating or reducing moderate toxicities. Focused reductions of certain toxicities may improve treatment adherence.

Topics & Keywords

Economic and Environmental Valuation Pharmaceutical studies and practices

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Patient Preference and Adherence

Volume 5, pp. 307-307

DOI: 10.2147/ppa.s20445

Field-Weighted Citation Impact: 6.53